Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Bristol Myers Squibb’s Camzyos shows sustained efficacy in 56-week pediatric heart disease trial

By Public Technologies
  • Bristol Myers Squibb presented 56-week Phase 3 SCOUT-HCM results for Camzyos in adolescents with symptomatic obstructive hypertrophic cardiomyopathy.
  • Treatment sustained reductions in heart outflow obstruction, with meaningful symptom improvements consistent with earlier results.
  • No new safety signals emerged; no participants experienced the specified decline in the heart’s pumping function during follow-up.
  • The FDA cleared Camzyos in September 2026 for pediatric patients weighing at least 30 kilograms, based on earlier 28-week results.
  • Additional clinical and real-world findings will be presented at the American Heart Association’s Scientific Sessions, November 6-9, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 202611061600BIZWIRE_USPR_____20261105_BW324472) on November 06, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.